Farmas USA

Muy agradecido. En lugar de puts , no lo ves estructurando un straddle?

Es justo lo que recomiendo en el hilo de Arena. Pero también puedes comprar y cubrirte con puts...

Léetelo, anda... :D

Hola Jorge A, donde ves suelo a Peregrine Pharmaceuticals Inc?? Me preguntaba donde puede parar. Ya se que es complicado pero vamos por si hubiera algo que te hiciera pensar que no va a bajar de 0,**??

Ni idea. Lo único que se, es que por más noticias supuestamente favorables que sacan, la acción sigue cayendo. Me temo que cualquier día los inversores les cierran el grifo.

Nunca me meto en una acción así... ya sabes, lo de los cuchillos cuando caen. Prefiero esperar a que hagan suelo, remonten algo, y luego ya se verá. Que el primer dólar, no sólo el último, también lo gane otro...

S2

Galena Biopharma (GALE)

Galena Biopharma began trading higher on January 5 when it announced the approval for a Phase II trial with the treatment of NeuVax and Herceptin. Almost immediately the stock began to trade higher as optimism surrounding the company's lead candidate, NeuVax, and was encouraged by several key developments, including a patent on the drug and a dividend payment in the form of RXI shares. As a late stage candidate, NeuVax's potential has become an area of optimism, as a result of few treatments in breast cancer and NeuVax being the most advanced treatment under-development. As a result, the stock posted a Q1 gain of 373% due to it being significantly undervalued at the beginning of the year.

Much like THLD, GALE has performed with loss during the first few days of the Q2, a loss of 15%. However, the stock has several short-term catalysts for growth that could spark additional gains, especially considering its value-presenting price. The company will present 48-month data at the ASCO meeting regarding the long-term durability of NeuVax. This could help prove breast cancer to be a maintenance disease that includes boosters every six months, which would be good for patients and give GALE much stronger commercial opportunities. The company is also planning to have 100 clinical sites enrolled for its Phase III trial by mid-2012, which is important to investors. The NeuVax with Herceptin combination study is expected to start near the same time, and if successful could open several revenue producing doors. Overall, I believe the stock is undervalued considering potential, and believe there are enough short-term catalysts to result in a high

Como veis esta Farma parece que tiene algo que presentar? s2

De acuerdo. Esperaré. A ver si se estabiliza. Gracias.

Aunque seekingalpha no es mi fuente favorita en términos de fiabilidad, os paso el vínculo de un par de artículos -o, mejor dicho, de un artículo en dos partes- que es interesante analizando las biotech con mejor evolución en Q1 '12

S2

Which Q1 Biotech Movers Can Build Off Momentum?

http://seekingalpha.com/article/493861-which-q1-biotech-movers-can-build-off-momentum?
http://seekingalpha.com/article/493871-which-q1-biotech-movers-can-build-off-momentum-part-ii?

Entro en Cord Blood America. Esto es la pera si tuvieran valor... 56.789 acciones. y sube un 4% jajaja. Venga que parezco el máximo accionista. Lo he hecho porque me hacia ilusión tener mas de 50mil acciones de algo.